1421371-97-2

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-2-methoxy-5-nitrobenzenamine is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its specific functional groups allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-2-methoxy-5-nitrobenzenamine serves as an intermediate in the production of active ingredients for pesticides and other agrochemical products, contributing to the development of effective solutions for crop protection and management.
Used in Medicinal Chemistry:
4-bromo-2-methoxy-5-nitrobenzenamine is utilized as a building block in medicinal chemistry for the design and synthesis of complex molecules with potential medicinal properties. Its unique structure facilitates the creation of novel drug candidates for various therapeutic areas.

Upstream product

• 59557-91-4 4-bromo-2-methoxyaniline 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 90-04-0 2-methoxy-phenylamine 
• 103966-66-1 4-bromo-2-methoxy-1-nitro-benzene 

Downstream Products

• 1421373-86-5 C₂₉H₃₀N₆O₂ 
• 1421373-89-8 C₂₇H₂₇N₇O₂ 
• 1421371-94-9 6-methoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{5-methyl-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl}benzene-1,3-diamine 
• 1421371-95-0 N-[2-methoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-5-nitrophenyl]-5-methyl-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-amine 
• 1421371-98-3 4-methoxy-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl}benzene-1,3-diamine 
• 1421371-99-4 N'-{4-[1-(benzenesulfonyl)indol-3-yl]-5-chloropyrimidin-2-yl}-4-methoxy-6-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)benzene-1,3-diamine 
• 1421372-00-0 4-[1-(benzenesulfonyl)indol-3-yl]-5-chloro-N-[2-methoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-5-nitrophenyl]pyrimidin-2-amine 
• 1421372-21-5 N-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)-6-methoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)benzene-1,3-diamine 
• 1421372-22-6 5-chloro-N-[2-methoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-5-nitrophenyl]-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-amine 
• 1421372-99-7 4-methoxy-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl}benzene-1,3-diamine 
• 1421373-00-3 4-bromo-6-methoxy-N-[4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine 
• 1421373-06-9 4-methoxy-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{4-(1-methylindol-3-yl)pyrimidine-2-yl}benzene-1,3-diamine 
• 1421373-07-0 4-bromo-6-methoxy-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]-benzene-1,3-diamine 
• 1421373-14-9 4-methoxy-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl}benzene-1,3-diamine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors

On the basis of N-(3-amino-4-methoxyphenyl)acrylamide scaffold, a series of novel compounds containing 3-substitutional-1-methyl-1H-indole, 2-substitutional pyrrole or thiophene moieties were synthesized and their in vitro antiproliferation activities aga

EGFR tyrosine kinase of selective inhibitors of clinically significant mutant

Kinase can be prevented by the compound and the salt, especially epidermal growth factor receptor (EGFR,erbB-2,erbB-4) and kinase clinica important gatekeeper 'mutant'; and abnormal cell profilerative diseases such as cancers can be treated or improved.

FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR

Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.